Pressure Biosciences

PBIO · OTC

$0.0005+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.0005

Key indicators

PBIO profitability and balance sheet ratios

EPS -$0.1384 in Jun 2024, against -$0.3554 a year earlier.

EPS by quarter
PeriodEPS
Sep 2022-$0.4007
Dec 2022-$0.3447
Mar 2023-$0.4331
Jun 2023-$0.3554
Sep 2023-$0.2592
Dec 2023-$0.3063
Mar 2024-$0.2028
Jun 2024-$0.1384

Where the money went

Q1 FY12, from revenue to net income

Pressure Biosciences brought in $0.3M of revenue in Q1 FY12, +69.2% on a year earlier. It made a net loss of $1.1M.

Revenue
$0.3M
Costs, expenses and taxes
$1.4M
Net income
−$1.1M
Net margin
-355.7%

Income statement

Revenue and profit by reporting period

Revenue
Net income
PBIO income statement, quarterly
Line itemQ3 FY11Q4 FY11Q1 FY12
Revenue$0.3M$0.3M$0.3M
Gross profit$0.2M$0.2M$0.2M
Operating income−$0.7M−$0.9M−$1.0M
Net income−$1.0M−$2.0M−$1.1M
Diluted EPS-$4.50-$8.10-$4.20

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
PBIO balance sheet, quarterly
Line itemDec 2023Mar 2024Jun 2024
Total assets$1.0M$7.0M$6.9M
Total liabilities$33.8M$45.1M$44.1M
Shareholder equity−$32.8M−$38.1M−$37.2M
Cash and short-term investments$0.1M$0.0M$0.0M
Total debt$22.8M$26.5M$28.6M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
PBIO cash flow, quarterly
Line itemQ3 FY11Q4 FY11Q1 FY12
Operating cash flow−$0.3M−$0.8M−$0.6M
Investing cash flow$0.0M−$0.0M$0.0M
Financing cash flow$0.4M$0.7M$0.4M
Capital expenditure$0.0M−$0.0M$0.0M
Free cash flow−$0.3M−$0.8M−$0.6M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.